| Objective : The proliferation and metastasis of cancer cells have been found to be related to the regulation of protein metabolism in cancer cells.This field has become one of the hot areas in cancer research.Finding key and effective tumor target genes is now a difficult point in the field of lung cancer treatment.PYCR1 participates in proline metabolism by catalyzing the reduction of P5 C to proline and producing both NAD +and NADP +,Proline is a unique amino acid that is a key cornerstone of proteins and plays an important role in stress protection and redox balance in cells.It has been demonstrated that proline synthesis is increased in multiple cancers,PYCR1 in non-small cell lung cancer patient tissues and serum expression levels,and investigated its diagnostic efficacy and prognostic value in non-small cell lung cancer.Methods:1.Histological specimen examination: 61 lung cancer tissues and adjacent tissues of NSCLC patients in our thoracic surgery department who underwent surgery from July 2011 to January 2016 were collected for immunohistochemistry and the follow-up data were complete until January 2021.The expression of PYCR1 in its lung cancer tissues and adjacent cancer tissues was examined.The expression of PYCR1 in its lung cancer tissues and adjacent cancer tissues was examined.To further explore the association between PYCR1 expression and patient clinicopathological data,we analyzed the correlation of PYCR1 expression and the prognosis of NSCLC patients by the Kaplan-Meier survival curve and Cox proportional hazards model.2.The 70 patients who presented to the Department of Respiratory Medicine from June 2020 to June 2021 and had the initial diagnosis of NSCLC by fibrobronchoscopy,percutaneous lung puncture biopsy and internal thoracoscopic pathology were collected into the experimental group.A total of 50 patients coming to the hospital for physical examination were selected as the control group.Human PYCR1 content in the specimens was obtained by standard curves by double antibody sandwich.We combined the patient clinicopathological data to explore the relationship between PYCR1 serum expression level and the patient clinicopathological characteristics,and clarified the diagnostic efficacy of NSCLC through the subject working characteristic curve(receiver operating characteristic curve,ROC).Result: 1.Immunohistochemical results showed that the expression of PYCR1 was increased in lung cancer tissues and not in adjacent cancer tissues;combined with the clinical pathological data of patients,32 cases of PYCR1(52.46%)and low expression(47.54%),with expression associated with lymph node metastasis(P=0.021),clinical stage(P=0.005),tumor size(P=0.087),pathological type(P=0.394)and differentiation(P=0.786).Kaplan-Meier survival curves showed that increased PYCR1 expression suggests poor prognosis in patients.Patients with high PYCR1 expression had a significantly lower survival time than those with low expression.Patients with stage lung cancer had significantly less survival time than stage I and stage I.No differences were found in the survival curves across the pathological types.Univariate analysis showed patient survival and clinical stage(P < 0.001),High PYCR1 expression(P=0.032)was associated with lymph node metastasis(P=0.028).Multivariate analysis showed that high PYCR1 protein expression is an independent risk factor for poor prognosis in NSCLC patients(HR:2.367,95%CI:1.164-5.235,P = 0.002).2.The expression level of PYCR1 protein in the serum of 70 NSCLC patients was(1057.62 ± 114.39)ng/m L,while the expression level of PYCR1 protein was(287.83 ±43.25)ng/m L in 50 healthy control patients(P<0.001).In the stage I + II group,the serum expression level of PYCR1 protein was(865.41 ± 110.09)ng/m L,which was significantly lower than that of(1275.68 ± 119.42)in the stage III + IV group(P <0.05).The serum expression level of PYCR1 protein in patients with no lymph node metastasis was(836.27 ± 98.78),(1235.34 ± 112.06)ng/m L in lymph node metastasis,and PYCR1 was significantly higher than that without lymph node metastasis(P <0.05).The results of establishing the ROC curve showed that when PYCR1 was selected as 627.24ng/m L,the specificity of NSCLC was 76.92% and the sensitivity was89.66%.Combined with carcinoembryonic antigen(CEA),cytokeratin 19 fragment(cytokeratin-19-feagment-CYFRA21-1),the specificity was 84.62% and the sensitivity was 90.43%.Conclusion: 1.Increased expression of PYCR1 in NSCLC lung cancer tissues is closely related to prognosis and is an independent risk factor for prognosis.2.PYCR1,which increased in peripheral blood in non-small cell lung cancer and further increased in patients with high clinical stage and lymph node metastasis,showed good detection efficacy with the three indicators of CEA and CYFRA21-1. |
PDF Full Text Request